Výsledky vyhledávání - "Neil L Berinstein"

Akademický článek

Increased immune infiltration and chemokine receptor expression in head and neck epithelial tumors after neoadjuvant immunotherapy with the IRX-2 regimen

Autor: Neil L. Berinstein, Michael McNamara, Ariane Nguyen, James Egan, Gregory T. Wolf

Publikováno v: OncoImmunology, Vol 7, Iss 5 (2018)

IRX-2 is an injectable cancer immunotherapy composed of cytokines purified from stimulated normal-donor peripheral blood mononuclear cells. In a phase 2a trial (n = 27), neoadjuvant IRX-2 significantly increased lymphocyte infiltration (LI) into rese

Externí odkaz: https://doaj.org/article/c9d89f8f4c364279bfdbd6c8fd6c174c

Zobrazit plný text záznamu

Akademický článek

Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide

Autor: Olga Hrytsenko, Marc Mansour, Tara Quinton, Genevieve M. Weir, Neil L. Berinstein, Marianne M. Stanford

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 4, Iss 1 (2016)

Background Future cancer immunotherapies will combine multiple treatments to generate functional immune responses to cancer antigens through synergistic, multi-modal mechanisms. In this study we explored the combination of three distinct immunotherap

Externí odkaz: https://doaj.org/article/fcc0b55106294739b12e926b29b0f54b

Zobrazit plný text záznamu

Abstract P2-09-12: Perilymphatic IRX-2 cytokine therapy to enhance tumor infiltrating lymphocytes (TILs) and PD-L1 expression preceding curative-intent therapy in early stage breast cancer (ESBC)

Autor: Walter J. Urba, M Campbell, Neil L Berinstein, Joanna Pucilowska, Maritza Martel, A Acheson, M Shah, Zhaoyu Sun, David B. Page, K Massimino, William L. Redmond, S Aliabadi-Wahle, Nicole Moxon, JH Imatani, Yaping Wu, Alison Conlin, JE Egan

Publikováno v: Cancer Research. 79:P2-09

Background: Cytokines are being explored as a therapeutic strategy to modulate the tumor microenvironment and facilitate immunotherapy benefit in breast cancer. Here, we investigate a locoregional therapeutic approach whereby cytokines (IRX-2) are ad

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f7e1bc1cedf98a5e2df2ee14b573d3d0
https://doi.org/10.1158/1538-7445.sabcs18-p2-09-12

Zobrazit plný text záznamu

356 Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab

Autor: Iran Rashedi, Nick Forward, Neil L. Berinstein, Gail Klein, Isabelle Bence-Bruckler, Douglas A. Stewart, Rebekah Conlon, Pierre Laneuville, Irina Amitai, Kim Roos, Nancy Pennell, Joy Mangel, Yogesh Bramhecha

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)

Background Treatment of recurrent/refractory (r/r) DLBCL remains an unmet clinical need, and new effective and well-tolerated treatments are required. DPX-Survivac is a unique T cell activation therapy that targets survivin-expressing tumor cells and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca01c2b1eb1fdefcb3b0a02cc8a9bceb
https://doi.org/10.1136/jitc-2020-sitc2020.0356

Zobrazit plný text záznamu

S erum‐derived carcinoembryonic antigen ( CEA ) activates fibroblasts to induce a local re‐modeling of the extracellular matrix that favors the engraftment of CEA ‐expressing tumor cells

Autor: Aaron Prodeus, Marzena Cydzik, Samira Alminawi, Jean Gariépy, Aws Abdul-Wahid, Nicholas W. Fischer, Anne L. Martel, Neil L. Berinstein, John E. Shively, Zeina Ghorab

Publikováno v: International Journal of Cancer. 143:1963-1977

Elevated levels of the carcinoembryonic antigen (CEA; CEACAM5) in the serum of colorectal cancer (CRC) patients represent a clinical biomarker that correlates with disease recurrence. However, a mechanistic role for soluble CEA (sCEA) in tumor progre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::859980ca0da63befae4081bb7c2586e0
https://doi.org/10.1002/ijc.31586

Zobrazit plný text záznamu

IRX-2 natural cytokine biologic for immunotherapy in patients with head and neck cancers

Autor: Michael J. Kaplan, Jason G. Newman, James E. Egan, Jeffrey S. Moyer, Neil L. Berinstein, Gregory T. Wolf, Theresa L. Whiteside

Publikováno v: OncoTargets and therapy

Head and neck squamous cell carcinoma (HNSCC) is an immunosuppressive malignancy characterized by tumor-driven immune-system abnormalities that contribute to disease progression. For patients with surgically resectable HNSCC, treatment is often curat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4bb4d79e7da836218a23b20117c1ec7
https://doi.org/10.2147/ott.s165411

Zobrazit plný text záznamu

Plný text ve formátu HTML

Management of newly diagnosed high-risk and intermediate-risk follicular lymphoma with90Y ibritumomab tiuxetan in a phase II study

Autor: Marciano Reis, Rashmi Weerasinghe, Nancy Pennell, Matthew C. Cheung, Ellen Miles, Mary-Anne Cussen, Lisa Chodirker, Zeina Ghorab, Kevin Imrie, Rena Buckstein, Neil L. Berinstein, E. Piliotis

Publikováno v: Hematological Oncology. 36:525-532

Five-year overall survival for high-risk Follicular Lymphoma International Prognostic Index follicular lymphoma is only approximately 50% compared with 90% for low risk. To evaluate an approach to improve upon this poor outcome, we completed an explo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::896b655e3fe36e26ceac8333110b56e4
https://doi.org/10.1002/hon.2513

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání